J Gynecol Oncol.
2017 Jul;28(4):e54. 10.3802/jgo.2017.28.e54.
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
- Jang JY
- Yanaihara
- Pujade-Lauraine E
- Mikami Y
- Oda K
- Bookman M
- Ledermann
- Shimada M
- Kiyokawa T
- Kim BG
- Matsumura
- Kaku T
- Kuroda T
- Nagayoshi
- Kawabata A
- Iida Y
- Kim JW
- Quinn M
- Okamoto A
- Affiliations
-
- 1Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan. yanazou@jikei.ac.jp
- 2Unité Cancer de la Femme et Recherche Clinique, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, Université Paris Descartes, Paris, France.
- 3Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.
- 4Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
- 5US Oncology Research and Arizona Oncology, Tucson, AZ, USA.
- 6UCL Cancer Institute, University College London, London, UK.
- 7Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
- 8Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
- 9Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 10Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
- 11Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
- 12Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea.
- 13Women's Cancer Research Center, Royal Women's Hospital, Melbourne, Australia.
- KMID: 2413437
- DOI: http://doi.org/10.3802/jgo.2017.28.e54
Abstract
- There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
Keyword
MeSH Terms
-
Adenocarcinoma, Clear Cell/genetics/pathology/therapy
Adenocarcinoma, Mucinous/diagnosis/pathology/therapy
Antineoplastic Agents/*therapeutic use
Congresses as Topic
Cytoreduction Surgical Procedures
Female
Fertility Preservation
Humans
Molecular Targeted Therapy
Neoplasm Grading
Neoplasms, Glandular and Epithelial/genetics/*pathology/*therapy
Ovarian Neoplasms/genetics/*pathology/*therapy
Ovariectomy
Rare Diseases/*pathology/*therapy
Antineoplastic Agents
